Compare GAM & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAM | ALMR |
|---|---|---|
| Founded | 1927 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2026 |
| Metric | GAM | ALMR |
|---|---|---|
| Price | $62.86 | $26.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.6K | ★ 243.4K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.09 | $21.58 |
| 52 Week High | $66.18 | $24.58 |
| Indicator | GAM | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | N/A |
| Support Level | $62.50 | N/A |
| Resistance Level | $62.83 | N/A |
| Average True Range (ATR) | 1.05 | 0.00 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 27.04 | 0.00 |
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.